Compile Data Set for Download or QSAR
Report error Found 44 Enz. Inhib. hit(s) with all data for entry = 10250
TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522958(US11161852, Compound 1 | 1-(4-(4-amino-7- (oxetan-...)
Affinity DataIC50: 225nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522987(US11161852, Compound 10 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 225nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523015(US11161852, Compound 45 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 225nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522989(US11161852, Compound 12 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 225nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523007(US11161852, Compound 35 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 225nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522991(US11161852, Compound 14 | 1-(4-(4-amino-7-(2- hydr...)
Affinity DataIC50: 225nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523005(US11161852, Compound 30 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 225nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523003(US11161852, Compound 28 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 225nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522959(US11161852, Compound 6 | 1-(4-(4-amino-7- cyclopro...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523022(US11161852, Compound 56 | 1-(4-(4-amino-7-(1- meth...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523019(US11161852, Compound 53 | 1-(4-(4-amino-7- cyclobu...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523006(US11161852, Compound 31 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523004(US11161852, Compound 29 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523002(US11161852, Compound 26 | 1-(4-(4-amino-7-(1- meth...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522999(US11161852, Compound 23 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522988(US11161852, Compound 11 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522995(US11161852, Compound 19 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522990(US11161852, Compound 13 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 400nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523000(US11161852, Compound 24 | 1-(4-(4-amino-7- (pyridi...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523001(US11161852, Compound 25 | 1-(4-(4-amino-7- (pyridi...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523014(US11161852, Compound 44 | 1-(5-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523023(US11161852, Compound 58 | 1-(4-(4-amino-7- cyclobu...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522972(US11161852, Compound 7 | 1-(4-(4-amino-7- cyclopro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523008(US11161852, Compound 36 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523009(US11161852, Compound 38 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522983(US11161852, Compound 8 | 1-(4-(4-amino-7- cyclopro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523012(US11161852, Compound 42 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.00E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523018(US11161852, Compound 50 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523026(US11161852, Compound 62 | US11713321, Example 62)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523020(US11161852, Compound 54 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523021(US11161852, Compound 55 | 1-(4-(4-amino-7-c yclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523024(US11161852, Compound 59 | 1-(6-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523025(US11161852, Compound 60 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522998(1-(4-(4-amino-7- cyclopropyl-7H- pyrrolo[2,3- d]py...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523017(US11161852, Compound 49 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523016(US11161852, Compound 48 | 1-(5-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523013(US11161852, Compound 43 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523011(US11161852, Compound 41 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM523010(US11161852, Compound 40 | 1-(6-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522992(US11161852, Compound 15 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522993(US11161852, Compound 16 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522994(US11161852, Compound 18 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522996(US11161852, Compound 20 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase Nek7(Human)
Halia Therapeutics

US Patent
LigandPNGBDBM522997(US11161852, Compound 21 | 1-(4-(4-amino-7- cyclopr...)
Affinity DataIC50: 1.50E+3nMAssay Description:Casein substrate (from bovine milk, hydrolyzed and partially dephosphorylated mixture of α, β and a caseins, obtained from Sigma Aldrich, c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/20/2022
Entry Details
Go to US Patent